Concurrent Nimotuzumab with Radiation Therapy in Locally Advanced Cancers of Oropharynx and Hypopharynx: A Review of 6 Cases

B. Ravi  Shankar; Poojar  Kiran; B. V.  Madhavi; E.  Vijay

doi:10.4236/jct.2015.64042

JCT Vol.6 No.4 , April 2015

Concurrent Nimotuzumab with Radiation Therapy in Locally Advanced Cancers of Oropharynx and Hypopharynx: A Review of 6 Cases

B. Ravi Shankar¹, Poojar Kiran², B. V. Madhavi³, E. Vijay⁴

Abstract: Background: The prevalence of head and neck cancers in the world is around 57% and predominantly occurs in Asian countries. It accounts for 30% of all cancers in India. The cure rate of locally advanced squamous cell carcinoma of the head and neck (SCCHN) has only 30% - 60% even after combined therapeutic approaches. Epidermal Growth Factor Receptor (EGFR) antagonists are the most researched targets in the management of head and neck cancers. Claims at superior tumor control and additional survival benefit without any added toxicity make it an attractive option. With this case series we intend to see how nimotuzumab, a humanized monoclonal antibody, fares in difficult cases of head and neck cancers. Case Description: In this case series, total six patients of locally advanced cancer of head and neck region were treated weekly using cisplatin and nimotuzumab concurrently with radiation therapy (RT) for 6 - 7 weeks. Depending upon the disease stage as well as the general condition of the patient, different dose cycles and radiation doses were tailored. Patients were monitored for regular physical examinations and hematological tests followed by pre and post treatment computed tomography (CT) scans, Fludeoxyglucose positive emission tomography (FDG PET-CT) scans, and histopathology. All patients were assessed for toxicities and managed consequently. After completion of radiation and follow-up, 6 weeks later post treatment CT scans were carried out. Conclusion: This case series shows that combination of chemoradiation with nimotuzumab achieved good response rates with no evidence of residual disease/disease progression on follow-up. The patients’ tolerability with combination therapy was good and toxicity was acceptable. Nimotuzumab was found beneficial in combination with chemoradiation for locally advanced head and neck cancers.

Keywords: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Nimotuzumab, Epidermal Growth Factor Receptor (EGFR), Chemoradiation Therapy

Cite this paper: Shankar, B. , Kiran, P. , Madhavi, B. and Vijay, E. (2015) Concurrent Nimotuzumab with Radiation Therapy in Locally Advanced Cancers of Oropharynx and Hypopharynx: A Review of 6 Cases. Journal of Cancer Therapy, 6, 390-398. doi: 10.4236/jct.2015.64042.

References

[1] Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917.
http://dx.doi.org/10.1002/ijc.25516

[2] Brockstein, B.E. (2011) Management of Recurrent Head and Neck Cancer: Recent Progress and Future Directions. Drugs, 71, 1551-1559.
http://dx.doi.org/10.2165/11592540-000000000-00000

[3] Koness, R.J., Glicksman, A., Liu, L., Coachman, N., Landman, C., Slotman, G., et al. (1997) Recurrence Patterns with Concurrent Platinum-Based Chemotherapy and Accelerated Hyperfractionated Radiotherapy in Stage III and IV Head and Neck Cancer Patients. The American Journal of Surgery, 174, 532-535.
http://dx.doi.org/10.1016/S0002-9610(97)81724-2

[4] Brockstein, B., Haraf, D.J., Rademaker, A.W., Kies, M.S., Stenson, K.M., Rosen, F.B., et al. (2004) Patterns of Failure, Prognostic Factors and Survival in Locoregionally Advanced Head and Neck Cancer Treated with Concomitant Chemoradiotherapy: A 9-Year, 337-Patient, Multi-Institutional Experience. Annals of Oncology, 15, 1179-1186.
http://dx.doi.org/10.1093/annonc/mdh308

[5] Hama, T., Yuza, Y., Saito, Y., O-uchi, J., Kondo, S., Okabe, M., et al. (2009) Prognostic Significance of Epidermal Growth Factor Receptor Phosphorylation and Mutation in Head and Neck Squamous Cell Carcinoma. The Oncologist, 14, 900-908.
http://dx.doi.org/10.1634/theoncologist.2009-0058

[6] Russell, J.S. and Colevas, A.D. (2012) The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck. Chemotherapy Research and Practice, 2012, Article ID: 761518.
http://dx.doi.org/10.1155/2012/761518

[7] Duffaud, F. and Therasse, P. (2000) New Guidelines to Evaluate the Response to Treatment in solid Tumors. Bulletindu Cancer, 87, 881-886.

[8] Kassis, J., Lauffenburger, D.A., Turner, T. and Wells, A. (2001) Tumor Invasion as Dysregulated Cell Motility. Seminarsin Cancer Biology, 11, 105-119.
http://dx.doi.org/10.1006/scbi.2000.0362

[9] Akashi, Y., Okamoto, I., Iwasa, T., Yoshida, T., Suzuki, M., Hatashita, E., et al. (2008) Enhancement of the Antitumor Activity of Ionizing Radiation by Nimotuzumab, a Humanized Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Non-Small Cell Lung Cancer Cell Lines of Differing Epidermal Growth Factor Receptor Status. British Journal of Cancer, 98,749-755.
http://dx.doi.org/10.1038/sj.bjc.6604222

[10] Boland, W.K. and Bebb, G. (2009) Nimotuzumab: A Novel Anti-EGFR Monoclonal Antibody That Retains Anti-EGFR Activity While Minimizing Skin Toxicity. Expert Opinion on Biological Therapy, 9, 1199-1206.
http://dx.doi.org/10.1517/14712590903110709

[11] Rojo, F., Gracias, E., Villena, N., Cruz, T., Corominas, J.M., Corradino, I., et al. (2010) Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. Clinical Cancer Research, 16, 2474-2482.
http://dx.doi.org/10.1158/1078-0432.CCR-09-3042

[12] Crombet, T., Osorio, M., Cruz, T., Roca, C., del Castillo, R., Mon, R., et al. (2004) Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination with Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients. Journal of Clinical Oncology, 22, 1646-1654.
http://dx.doi.org/10.1200/JCO.2004.03.089

[13] Fountzilas, G., Kosmidis, P., Avramidis, V., Nikolaou, A., Kalogera-Fountzila, A., Makrantonakis, P., et al. (1997) Long-Term Survival Data and Prognostic Factors of a Complete Response to Chemotherapy in Patients with Head and Neck Cancer Treated with Platinum-Based Induction Chemotherapy: A Hellenic Cooperative Oncology Group Study. Medical and Pediatric Oncology, 28, 401-410.
http://dx.doi.org/10.1002/(SICI)1096-911X(199706)28:6<401::AID-MPO2>3.3.CO;2-0

[14] Babu, K.G., Viswanath, L., Reddy, B.K., Shenoy, K., Shenoy, A., Naveen, T., et al. (2010) An Open-Label, Randomized, Study of h-R3mAb (Nimotuzumab) in Patients with Advanced (Stage III or IVa) Squamous Cell Carcinoma of Head and Neck (SCCHN): Four-Year Survival Results from a Phase IIb Study. Journal of Clinical Oncology, 28, 15S.

[15] Fletcher, G.H. (1980) Textbook of Radiotherapy. 3rd Edition, Lea and Febiger, Philadelphia.

[16] Rodriguez, M.O., Rivero, T.C., del Castillo Bahi, R., Muchuli, C.R., Bilbao, M.A., Vinageras, E.N., et al. (2010) Nimotuzumab plus Radiotherapy for Unresectable Squamous-Cell Carcinoma of the Head and Neck. Cancer Biology and Therapy, 9, 343-349.
http://dx.doi.org/10.4161/cbt.9.5.10981

[17] Brizel, D.M., Wasserman, T.H., Henke, M., Strnad, V., Rudat, V., Monnier, A., et al. (2000) Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer. Journal of Clinical Oncology, 18, 3339-3345.

[18] Koukourakis, M.I., Kyrias, G., Kakolyris, S., Kouroussis, C., Frangiadaki, C., Giatromanolaki, A., et al. (2000) Subcutaneous Administration of Amifostine during Fractionated Radiotherapy: A Randomized Phase II Study. Journal of Clinical Oncology, 18, 2226-2233.